Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trialLaura Guay, J. Brooks Jackson, Mary Glenn Fowler et al.|The Lancet|1999Cited by 1.7k
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trialJ. Brooks Jackson, Francis Mmiro, Philippa Musoke et al.|The Lancet|2003Cited by 525
Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012)Susan H. Eshleman, J. Brooks Jackson, Martin Mracna et al.|AIDS|2001Cited by 422
A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006)Philippa Musoke, J. Brooks Jackson, Laura Guay et al.|AIDS|1999Cited by 217
Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmissionJ. Brooks Jackson, Susan H. Eshleman, Graziella Becker‐Pergola et al.|AIDS|2000Cited by 213